CYP4F3
Basic information
Region (hg38): 19:15640897-15662825
Previous symbols: [ "LTB4H" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
- not_specified (86 variants)
- not_provided (12 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CYP4F3 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000000896.3. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 3 | |||||
missense | 81 | 88 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
Total | 0 | 0 | 81 | 7 | 3 |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CYP4F3 | protein_coding | protein_coding | ENST00000221307 | 12 | 21929 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.54e-16 | 0.0105 | 125414 | 0 | 334 | 125748 | 0.00133 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.896 | 371 | 326 | 1.14 | 0.0000205 | 3415 |
Missense in Polyphen | 97 | 82.279 | 1.1789 | 954 | ||
Synonymous | 0.0598 | 129 | 130 | 0.993 | 0.00000788 | 1026 |
Loss of Function | 0.0793 | 24 | 24.4 | 0.983 | 0.00000104 | 281 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00503 | 0.00498 |
Ashkenazi Jewish | 0.00119 | 0.00119 |
East Asian | 0.000218 | 0.000217 |
Finnish | 0.000231 | 0.000231 |
European (Non-Finnish) | 0.000917 | 0.000897 |
Middle Eastern | 0.000218 | 0.000217 |
South Asian | 0.00164 | 0.00163 |
Other | 0.00131 | 0.00130 |
dbNSFP
Source:
- Function
- FUNCTION: Isoform CYP4F3A: Catalyzes the omega-hydroxylation of leukotriene-B(4), a potent chemoattractant for polymorphonuclear leukocytes, it has low activity for arachidonic acid. {ECO:0000269|PubMed:11461919, ECO:0000269|PubMed:8486631}.;
- Pathway
- Arachidonic acid metabolism - Homo sapiens (human);Etodolac Action Pathway;Ketoprofen Action Pathway;Ibuprofen Action Pathway;Rofecoxib Action Pathway;Acetylsalicylic Acid Action Pathway;Diflunisal Action Pathway;Leukotriene C4 Synthesis Deficiency;Acetaminophen Action Pathway;Celecoxib Action Pathway;Sulindac Action Pathway;Diclofenac Action Pathway;Ketorolac Action Pathway;Naproxen Action Pathway;Etoricoxib Action Pathway;Carprofen Action Pathway;Flurbiprofen Action Pathway;Fenoprofen Action Pathway;Antrafenine Action Pathway;Antipyrine Action Pathway;Lumiracoxib Action Pathway;Magnesium salicylate Action Pathway;Trisalicylate-choline Action Pathway;Nepafenac Action Pathway;Phenylbutazone Action Pathway;Lornoxicam Action Pathway;Salsalate Action Pathway;Tenoxicam Action Pathway;Tiaprofenic Acid Action Pathway;Tolmetin Action Pathway;Salicylic Acid Action Pathway;Salicylate-sodium Action Pathway;Oxaprozin Action Pathway;Valdecoxib Action Pathway;Nabumetone Action Pathway;Indomethacin Action Pathway;Meloxicam Action Pathway;Suprofen Action Pathway;Bromfenac Action Pathway;Mefenamic Acid Action Pathway;Arachidonic Acid Metabolism;Piroxicam Action Pathway;Oxidation by Cytochrome P450;Metapathway biotransformation Phase I and II;Phase I - Functionalization of compounds;Metabolism of lipids;Prostaglandin Leukotriene metabolism;Synthesis of Leukotrienes (LT) and Eoxins (EX);Arachidonic acid metabolism;Fatty acids;Eicosanoids;Miscellaneous substrates;Cytochrome P450 - arranged by substrate type;Leukotriene metabolism;Biological oxidations;Metabolism;Fatty acid metabolism;Putative anti-Inflammatory metabolites formation from EPA;Vitamin E metabolism;Arachidonic acid metabolism
(Consensus)
Intolerance Scores
- loftool
- 0.328
- rvis_EVS
- 0.25
- rvis_percentile_EVS
- 69.69
Haploinsufficiency Scores
- pHI
- 0.439
- hipred
- N
- hipred_score
- 0.131
- ghis
- 0.458
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.960
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cyp4f13
- Phenotype
Gene ontology
- Biological process
- icosanoid metabolic process;leukotriene metabolic process;leukotriene B4 catabolic process;oxidation-reduction process
- Cellular component
- endoplasmic reticulum membrane;integral component of membrane;organelle membrane
- Molecular function
- monooxygenase activity;iron ion binding;heme binding;leukotriene-B4 20-monooxygenase activity;20-hydroxy-leukotriene B4 omega oxidase activity;20-aldehyde-leukotriene B4 20-monooxygenase activity